SKLB06329
SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs) . SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Histone Methyltransferase
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
CN(CC1=NNC2=CC=C(C=C21)C3=CC=C(C=C3)NS(=O)(C4CC4)=O)CCN
Molecular Formula
C20H25N5O2S
Molecular Weight
399.51
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PRMT6
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Prostatic Acid Phosphatase/ACPP protein (His tag)
Recombinant Human Prostatic Acid Phosphatase/ACPP protein (His tag)
Recombinant Human Prostatic Acid Phosphatase/ACPP protein (His tag)